{"id":773757,"date":"2023-07-31T11:00:23","date_gmt":"2023-07-31T15:00:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/"},"modified":"2023-07-31T11:00:23","modified_gmt":"2023-07-31T15:00:23","slug":"renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/","title":{"rendered":"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference"},"content":{"rendered":"

<\/p>\n

RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference<\/b><\/p>\n

LOS ALTOS, Calif.–(BUSINESS WIRE<\/a>)–RenovoRx, Inc<\/a>. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd<\/sup> Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA. Register here<\/a> to access the live webcast.<\/p>\n

\nMr. Bagai will discuss recent Company milestones, including the research collaboration with Imugene (ASX: IMU), and highlights from RenovoRx\u2019s open label pivotal Phase III TIGeR-PaC study. The TIGeR-PaC study is evaluating the proprietary TAMP\u2122 (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). Interim data demonstrates a 6-month overall survival benefit, 8-month delay in cancer progression, and 65% reduction in adverse effects over systemic (intravenous) chemotherapy. The data, presented at the recent 2023 ESMO World Congress on Gastrointestinal Cancer, drove the decision from the TIGeR-PaC Data Monitoring Committee (DMC) to continue this pivotal trial.<\/p>\n

43rd Annual Canaccord Genuity Growth Conference
\n
<\/span><\/b>Date:<\/b> August 10, 2023
\n
Time:<\/b> 10:30 \u2013 10:55 AM ET
\n
Speaker<\/b>: Shaun Bagai, CEO of RenovoRx
\n
Location:<\/b> Boston, Massachusetts
\n
Webcast:<\/b>https:\/\/wsw.com\/webcast\/canaccord89\/rnxt\/2519572<\/a><\/b><\/p>\n

\nTo schedule a one-on-one investor meeting with RenovoRx\u2019s management team, please contact a conference representative or KCSA Strategic Communications at RenovoRx@KCSA.com<\/a>.<\/p>\n

\nA webcast of the event will be available for a limited time in the Investors<\/a> section of the Company\u2019s website<\/a>.<\/p>\n

About RenovoRx, Inc.<\/b><\/p>\n

\nRenovoRx is a clinical-stage biopharmaceutical company developing targeted combination therapies for high unmet medical needs. The Company\u2019s proprietary Trans-Arterial Micro-Perfusion (TAMP\u2122) therapy platform is designed to bypass traditional systemic delivery methods and ensure precise therapeutic delivery to a target tissue, while minimizing a therapy\u2019s systemic toxicities. RenovoRx\u2019s unique approach to drug-delivery offers the potential for increased treatment safety, tolerance, and wider therapeutic windows. The Company\u2019s lead product candidate, RenovoGem\u2122 combines gemcitabine with the company\u2019s patented delivery system and is regulated by FDA under the IND 21 CFR 312 pathway. RenovoGem is currently in a Phase III clinical trial (TIGeR-PaC) for the treatment of locally advanced pancreatic cancer, where interim analysis has demonstrated a 6-month overall survival benefit, 8-month delay in cancer progression, and 65% reduction in adverse effects over systemic (intravenous) chemotherapy. RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale.<\/p>\n

\nFor more information, visit www.renovorx.com<\/a>. Follow RenovoRx on Facebook<\/a>, LinkedIn<\/a> and Twitter<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230731606568\/en\/<\/a><\/span><\/p>\n

Investor Contact:
\n<\/b>
KCSA Strategic Communications
\n
Valter Pinto or Jack Perkins
\n
T:212-896-1254
\n
renovorx@kcsa.com<\/a><\/p>\n

Media Contact:
\n<\/b>
KKH Advisors
\n
Kimberly Ha
\n
T: 917 291-5744
\n
kimberly.ha@kkhadvisors.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts California New York United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Other Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA. Register here to access the live webcast. Mr. Bagai will discuss recent Company milestones, including the research collaboration with Imugene (ASX: IMU), and highlights from RenovoRx\u2019s open label pivotal Phase III TIGeR-PaC study. The TIGeR-PaC study is evaluating the proprietary TAMP\u2122 (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). Interim data … <\/p>\n

Continue reading “RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-773757","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA. Register here to access the live webcast. Mr. Bagai will discuss recent Company milestones, including the research collaboration with Imugene (ASX: IMU), and highlights from RenovoRx\u2019s open label pivotal Phase III TIGeR-PaC study. The TIGeR-PaC study is evaluating the proprietary TAMP\u2122 (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). Interim data … Continue reading "RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-31T15:00:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230731606568r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference\",\"datePublished\":\"2023-07-31T15:00:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\\\/\"},\"wordCount\":501,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230731606568r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\\\/\",\"name\":\"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230731606568r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-07-31T15:00:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230731606568r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230731606568r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference - Market Newsdesk","og_description":"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (\u201cRenovoRx\u201d or the \u201cCompany\u201d) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA. Register here to access the live webcast. Mr. Bagai will discuss recent Company milestones, including the research collaboration with Imugene (ASX: IMU), and highlights from RenovoRx\u2019s open label pivotal Phase III TIGeR-PaC study. The TIGeR-PaC study is evaluating the proprietary TAMP\u2122 (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). Interim data … Continue reading \"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-31T15:00:23+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230731606568r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference","datePublished":"2023-07-31T15:00:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/"},"wordCount":501,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230731606568r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/","name":"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230731606568r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-07-31T15:00:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230731606568r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230731606568r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/renovorx-to-present-at-the-43rd-annual-canaccord-genuity-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/773757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=773757"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/773757\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=773757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=773757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=773757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}